Equities Analysts Set Expectations for BNTC Q3 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC) – HC Wainwright lifted their Q3 2026 earnings per share estimates for Benitec Biopharma in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings of ($0.25) per share for the quarter, up from their previous estimate of ($0.27). HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.97) EPS and FY2027 earnings at ($1.41) EPS.

A number of other brokerages also recently commented on BNTC. Wall Street Zen downgraded shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Zacks Research raised shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. TD Cowen reiterated a “buy” rating on shares of Benitec Biopharma in a report on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Benitec Biopharma Stock Up 7.0%

NASDAQ BNTC opened at $11.34 on Thursday. The business’s fifty day simple moving average is $11.79 and its 200-day simple moving average is $13.04. The firm has a market cap of $389.53 million, a PE ratio of -9.95 and a beta of 0.31. Benitec Biopharma has a 52 week low of $9.85 and a 52 week high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03).

Insider Buying and Selling at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 77,387 shares of Benitec Biopharma stock in a transaction dated Monday, December 29th. The shares were acquired at an average cost of $13.44 per share, with a total value of $1,040,081.28. Following the purchase, the director owned 9,700,195 shares of the company’s stock, valued at approximately $130,370,620.80. The trade was a 0.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have bought 190,364 shares of company stock worth $2,442,105 in the last ninety days. 4.80% of the stock is owned by company insiders.

Institutional Trading of Benitec Biopharma

Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new stake in Benitec Biopharma in the first quarter valued at approximately $597,000. Geode Capital Management LLC boosted its position in shares of Benitec Biopharma by 77.6% during the second quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company’s stock worth $4,859,000 after buying an additional 181,391 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Benitec Biopharma during the second quarter worth $38,000. JPMorgan Chase & Co. acquired a new stake in shares of Benitec Biopharma in the second quarter valued at $80,000. Finally, Rhumbline Advisers grew its stake in shares of Benitec Biopharma by 11,114.0% in the second quarter. Rhumbline Advisers now owns 20,858 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 20,672 shares in the last quarter. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.